ArticleScience (New York, N.Y.)2021
Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacy.
Open access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 58 citations in OpenAlex.
- Candidate correlates of protection in the HVTN505 HIV-1 vaccine efficacy trial identified by positive-unlabeled learning.PLoS computational biology · 2025Trial
- Nonclassical MHC-I Molecules: Emerging Therapeutic Targets in Next-Generation Immunotherapy.MedComm · 2026Review
- Non-cognate CD8 Binding to MHC I Promotes Positive Selection of an MHC-E Restricted CD8 T Cell Population.European journal of immunology · 2026Article
- The race between viral immune evasion and the MHC class I antigen processing pathway.FEMS microbiology reviews · 2026Review
- The murine MHC-E molecule Qa-1Frontiers in immunology · 2026Article
- Targeting MHC-E as a new strategy for vaccines and immunotherapeutics.Nature reviews. Immunology · 2026Review
- Shared HLA-E and Mamu-E Peptide Repertoires With Subtle Peptide Binding Differences Revealed by Combined nDSF- and Fluorescence Polarisation-Based Methods.European journal of immunology · 2026Article
- The Expanding Role of HLA-E in Host Defense: A Target for Broadly Applicable Vaccines and Immunotherapies.Cells · 2025Review
- A cytoplasmic motif in HLA-E that drives clathrin-mediated endocytosis and VCP-associated postendocytic trafficking.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Candidate Correlates of Protection in the HVTN505 HIV-1 Vaccine Efficacy Trial Identified by Positive-Unlabeled Learning.medRxiv : the preprint server for health sciences · 2025Article
- Glycoprotein L-deleted single-cycle rhesus cytomegalovirus vectors elicit MHC-E-restricted CD8+ T cells that protect against SIV.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Exploitation of Unconventional CD8 T-Cell Responses Induced by Engineered Cytomegaloviruses for the Development of an HIV-1 Vaccine.Vaccines · 2025Review
- Combining a rhesus cytomegalovirus/SIV vaccine with a neutralizing antibody to protect against SIV challenges in rhesus macaques.Frontiers in microbiology · 2025Article
- HLA-E: Immune Receptor Functional Mechanisms Revealed by Structural Studies.Immunological reviews · 2025Review
- Human cytomegalovirus UL18 prevents priming of MHC-E- and MHC-II-restricted CD8Science immunology · 2024Article
- Article
- Regulation of the cell surface expression of classical and non-classical MHC proteins by the human cytomegalovirus UL40 and rhesus cytomegalovirus Rh67 proteins.Journal of virology · 2024Article
- Mucosal T-cell responses to chronic viral infections: Implications for vaccine design.Cellular & molecular immunology · 2024Review
- Article
- Cytomegalovirus vaccine vector-induced effector memory CD4 + T cells protect cynomolgus macaques from lethal aerosolized heterologous avian influenza challenge.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 3 institutions in 2 countries.
Marieke C Verweij *Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID https://orcid.org/0000-0001-6556-8682
Scott G Hansen *Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID https://orcid.org/0000-0002-9845-6481
Ravi Iyer *Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID https://orcid.org/0000-0003-2249-266X
Nessy John *Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID https://orcid.org/0000-0002-4114-4946
Daniel MalouliVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID https://orcid.org/0000-0003-1287-7283
David MorrowVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID https://orcid.org/0000-0003-4686-830X
Isabel ScholzVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID https://orcid.org/0000-0002-1512-4394
Jennie WomackVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID https://orcid.org/0000-0002-4941-3696
Shaheed AbdulhaqqVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID https://orcid.org/0000-0001-8067-9698
Roxanne M GilbrideVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
Colette M HughesVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
Abigail B VenturaVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID https://orcid.org/0000-0002-8893-4769
Julia C FordVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID https://orcid.org/0000-0002-4989-2842
Andrea N SelsethVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID https://orcid.org/0000-0001-9536-463X
Kelli OswaldAIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.
Rebecca ShoemakerAIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.
Brian BerkemeierAIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.ORCID https://orcid.org/0000-0003-1215-5694
William J BoscheAIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.ORCID https://orcid.org/0000-0001-5367-2116
Michael HullAIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.
Jason ShaoPopulation Sciences and Computational Biology Programs, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID https://orcid.org/0000-0003-0830-0211
Jonah B SachaVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
Michael K AxthelmVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID https://orcid.org/0000-0002-1984-5906
Paul T EdlefsenPopulation Sciences and Computational Biology Programs, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID https://orcid.org/0000-0002-8393-8103
Jeffrey D LifsonAIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.ORCID https://orcid.org/0000-0002-9494-0268
Louis J PickerVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA. fruehk@ohsu.edu pickerl@ohsu.edu.ORCID https://orcid.org/0000-0003-0546-398X
Klaus FrühVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA. fruehk@ohsu.edu pickerl@ohsu.edu.ORCID https://orcid.org/0000-0001-8014-3877
Oregon National Primate Research Center · USFrederick National Laboratory for Cancer Research · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZA
Funding
Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9MConsortia for Innovative AIDS Research in Nonhuman PrimatesUM1AI124377 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., PICKER, LOUIS J. · 2016 to 2021
$53.0MVirology and Immunology MonitoringP01AI094417 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI PICKER, LOUIS J. · 2011 to 2016
$20.5MVirology and Vector Production Core CU19AI128741 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI PICKER, LOUIS J. · 2017 to 2021
$11.8MRole of Memory T Cell Dynamics in SIV InfectionR37AI054292 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI PICKER, LOUIS J. · 2008 to 2017
$9.8MEvasion of Antigen Presentation by Rhesus CytomegalovirusR01AI059457 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI FRUH, KLAUS J · 2005 to 2021
$6.2MUnderstanding Unconventional CD8+ T cell Responses in Protection from HIVR01AI140888 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI HANSEN, SCOTT G, SACHA, JONAH B. · 2018 to 2023
$4.4MNon-canonical epitope presentation and antigen processing by MHC-ER01AI175459 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Klaus J Fruh, Jonah B. Sacha · 2023 to 2026
$2.8MCCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS P01 AI094417NIAID NIH HHS R01 AI059457NIAID NIH HHS R01 AI140888NIAID NIH HHS R01 AI175459NIAID NIH HHS R37 AI054292NIAID NIH HHS U19 AI128741NIAID NIH HHS UM1 AI124377NIH HHS P51 OD011092
Abstract
Strain 68-1 rhesus cytomegalovirus (RhCMV) vectors expressing simian immunodeficiency virus (SIV) antigens elicit CD8
Indexed as
AnimalsCD8-Positive T-LymphocytesCell LineCytomegalovirusEpitopes, T-LymphocyteFibroblastsGenetic VectorsHistocompatibility Antigens Class IHLA-E AntigensLigandsMacaca mulattaPeptide FragmentsProtein TransportSAIDS VaccinesSimian Immunodeficiency VirusEpitopes, T-LymphocyteHistocompatibility Antigens Class IHLA-E AntigensLigandsPeptide FragmentsSAIDS Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.